According to FutureWise analysis the market for Guillain-Barre Syndrome in 2023 is US$ 0.41 billion, and is expected to reach US$ 0.63 billion by 2031 at a CAGR of 5.42%.
One of the most common risk factors for developing Guillain-Barre syndrome is infection with the bacteria Campylobacter jejuni. After catching the flu or contracting the Cytomegalovirus or Epstein–Barr virus, the condition can emerge. Guillain-Barre syndrome can appear days or weeks after a vaccine. The senior population is at a higher risk of getting Guillain-Barre syndrome (GBS), according to the Centers for Disease Control and Prevention, because the condition's incidence rises with age. People over the age of 50 are at the greatest risk of contracting GBS. Guillain-Barre Syndrome is a rare neurological illness in which the body's immune system attacks the nervous system, which consists of a network of nerves outside the brain and spinal cord. Guillain-Barre Syndrome can range in severity from a minor weakening to a near-complete paralysis. Weakness and tingling in the extremities are frequently the first indications and symptoms. Around 80% of persons with Guillain-Barre can walk freely after six months, and 60% can regain their normal muscle strength after a year. After three years, about 30% of people still have some weakness. For the treatment of Guillain–Barré syndrome, intravenous immunoglobulins are used. Gamunex, Gammagard/Kiovig, and Privigen are IVIG medicines that are given at a dose of 0.4 g/kg of body weight every day for five days.
Guillain–Barre syndrome can be treated by plasma exchange. Other medications, such as analgesics, anticonvulsants, and low-molecular-weight heparin, are used to treat Guillain–Barré syndrome symptoms and consequences. Intravenous and subcutaneous modes of administration are used to give immunoglobulins. The intravenous method of administration is used to deliver albumin for plasma exchange in individuals with Guillain–Barré syndrome. Hospital pharmacies provide all medications for patients, as well as surgical supplies, speciality care goods, pathological supplies, and a 24-hour service. The Guillain–Barré syndrome market's primary distribution channel is hospital pharmacies.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Guillain-Barre Syndrome Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Guillain-Barre Syndrome Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.